Last reviewed · How we verify
PSA dosage
PSA dosage is used to measure the level of prostate-specific antigen in the blood, which can help diagnose and monitor prostate cancer.
PSA dosage is used to measure the level of prostate-specific antigen in the blood, which can help diagnose and monitor prostate cancer. Used for Prostate cancer screening and monitoring.
At a glance
| Generic name | PSA dosage |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PSA is a protein produced by the prostate gland, and elevated levels can indicate prostate cancer or other prostate conditions. The PSA dosage test measures the amount of PSA in the blood, which can help doctors diagnose and monitor prostate cancer, as well as monitor the effectiveness of treatment.
Approved indications
- Prostate cancer screening and monitoring
Common side effects
- Pain or discomfort during the biopsy procedure
Key clinical trials
- Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland (PHASE2)
- A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (PHASE3)
- A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health (NA)
- Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy (PHASE3)
- Hypo Fractionated Versus Conventional IMRT in Unfavorable Intermediate- and High-Risk Prostate Cancer (NA)
- Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis (PHASE3)
- Prostate Stereotactic Radiation and Radio-induced Lymphocyte Apoptosis for Predicting Late Toxicities in Prostate Cancer (PROSTERA) (NA)
- Radium-223 in Biochemically Recurrent Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |